LLY

1,014.52

-3.15%↓

JNJ

243.43

-0.55%↓

ABBV

224.55

-3.14%↓

NVS

165.62

-1.16%↓

MRK

120.01

-3.14%↓

LLY

1,014.52

-3.15%↓

JNJ

243.43

-0.55%↓

ABBV

224.55

-3.14%↓

NVS

165.62

-1.16%↓

MRK

120.01

-3.14%↓

LLY

1,014.52

-3.15%↓

JNJ

243.43

-0.55%↓

ABBV

224.55

-3.14%↓

NVS

165.62

-1.16%↓

MRK

120.01

-3.14%↓

LLY

1,014.52

-3.15%↓

JNJ

243.43

-0.55%↓

ABBV

224.55

-3.14%↓

NVS

165.62

-1.16%↓

MRK

120.01

-3.14%↓

LLY

1,014.52

-3.15%↓

JNJ

243.43

-0.55%↓

ABBV

224.55

-3.14%↓

NVS

165.62

-1.16%↓

MRK

120.01

-3.14%↓

Inicio・Lista de Acciones・AbCellera Biologics Inc

AbCellera Biologics Inc

Abierto

SectorSanidad

3.44 7.5

Comprar Vender

Resumen

Variación precio

24h

Actual

Mínimo

3.13

Máximo

3.34

Métricas clave
By Trading Economics
Ingresos	-22M -57M
Ventas	-8.1M 9M
Margen de beneficios	-637.845
Empleados	596
EBITDA	-1.4M -40M

Recomendaciones
By TipRanks
Recomendaciones	Compra Fuerte
Estimación a 12 Meses	+117.39% upside

Dividendos
By Dow Jones
Próximas Ganancias	7 may 2026

Estadísticas de Mercado
By TradingEconomics
Capitalización Mercado	-698M 907M
Apertura anterior	-4.06
Cierre anterior	3.44

Noticias sobre sentimiento de mercado

By Acuity

76%

24%

325 / 351 Clasificación en Healthcare

Puntuación técnica

By Trading Central

Confianza

Very Strong Bearish Evidence

1.99 / 2.635 Soporte y Resistencia

AbCellera Biologics Inc Gráfico

Resultados pasados no son un indicador fiable de resultados futuros.

Noticias Relacionadas

25 feb 2026, 23:25 UTC

Acciones populares

Stocks to Watch: C3.ai, Salesforce, Pure Storage, Zoom

25 feb 2026, 23:15 UTC

Ganancias

Salesforce Sees Stable Growth; CEO Dismisses Talk of AI-Fueled 'SaaS-Pocalypse' -- 2nd Update

25 feb 2026, 23:54 UTC

Charlas de Mercado

Gold Steady Ahead of U.S.-Iran Talks -- Market Talk

25 feb 2026, 23:47 UTC

Ganancias

Ferrovial 4Q Net EUR197M >FER.MC

25 feb 2026, 23:45 UTC

Ganancias

Ferrovial 4Q Rev EUR2.72B >FER.MC

25 feb 2026, 23:42 UTC

Ganancias

Nvidia Beats Back Bubble Fears With Record $68 Billion Sales in Fourth Quarter -- 4th Update

25 feb 2026, 23:38 UTC

Charlas de Mercado

Nikkei May Rise, Tracking Wall Street's Gains -- Market Talk

25 feb 2026, 23:25 UTC

Ganancias

Trip.com: Company's Business Operations Remain Normal >TCOM

25 feb 2026, 23:25 UTC

Ganancias

Trip.com Gives Update on Investigation by China's State Administration for Market Regulation >TCOM

25 feb 2026, 23:25 UTC

Ganancias

Trip.com: Cannot Predict Status or Results of Investigation, Will Provide Updates on Conclusion >TCOM

25 feb 2026, 23:25 UTC

Ganancias

Trip.com Increase in FY Profit Primarily Due to Gain From Investments >TCOM

25 feb 2026, 23:25 UTC

Ganancias

Trip.com Will Continue to Communicate With SAMR on Compliance With Regulatory Requirements >TCOM

25 feb 2026, 23:25 UTC

Ganancias

Trip.com: SAMR Investigation Related to China's Anti-monopoly Law >TCOM

25 feb 2026, 23:25 UTC

Ganancias

Trip.com: Investigation Ongoing, Company Is Cooperating With SAMR >TCOM

25 feb 2026, 23:25 UTC

Ganancias

Trip.com Co-founders Min Fan, Qi Ji Resign From Positions >TCOM

25 feb 2026, 23:25 UTC

Ganancias

Trip.com: Fan Resigned as Director and President; Ji Resigned as a Director >TCOM

25 feb 2026, 23:25 UTC

Ganancias

Trip.com FY Rev CNY62.4B, Up 17% >TCOM

25 feb 2026, 23:25 UTC

Ganancias

Trip.com FY Net CNY33.3B Vs. Net CNY17.1B >TCOM

25 feb 2026, 23:25 UTC

Ganancias

Trip.com FY EPS CNY47.67 >TCOM

25 feb 2026, 23:06 UTC

Ganancias

Correction to Nvidia Fourth Quarter Results Article -- WSJ

25 feb 2026, 23:01 UTC

Ganancias

Nvidia Beats Back Bubble Fears With Record $68 Billion Sales in Fourth Quarter -- 3rd Update

25 feb 2026, 23:00 UTC

Charlas de Mercado

Ganancias

Global Equities Roundup: Market Talk

25 feb 2026, 23:00 UTC

Charlas de Mercado

Ganancias

Nvidia: Chinese Competitors Pose Risk to U.S. Dominance in AI -- Market Talk

25 feb 2026, 22:56 UTC

Charlas de Mercado

Ganancias

Nvidia CEO Says Customers Can't Grow Revenue Without Compute -- Market Talk

25 feb 2026, 22:43 UTC

Ganancias

Adquisiciones, fusiones, absorciones

Paramount Streaming Revenue Rises, but TV Segment Faces Headwinds -- WSJ

25 feb 2026, 22:40 UTC

Charlas de Mercado

Ganancias

Nvidia Says Agentic AI Has Reached Inflection Point -- Market Talk

25 feb 2026, 22:40 UTC

Ganancias

Karoon Energy Says Search for New CFO Well Advanced

25 feb 2026, 22:39 UTC

Ganancias

Karoon Energy Says CFO Ray Church to Leave Company

25 feb 2026, 22:39 UTC

Ganancias

Karoon Energy Says On-Market Share Buyback Program Ongoing at Moderated Level

25 feb 2026, 22:38 UTC

Ganancias

Karoon Energy Says Guidance for 2026 Key Metrics Unchanged

Comparación entre iguales

Cambio de precio

AbCellera Biologics Inc previsión

Precio Objetivo

By TipRanks

117.39% repunte

Estimación a 12 Meses

Media 7 USD 117.39%

Máximo 7 USD

Mínimo 7 USD

De acuerdo con 4 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para AbCellera Biologics Inc Dist en los últimos 3 meses.

Consenso

By TipRanks

Compra Fuerte

4 ratings

Comprar

Mantener

Vender

De acuerdo con 4 analistas que ofrecen calificaciones bursátiles a para AbCellera Biologics Inc Dist en los últimos 3 meses.

Puntuación técnica

By Trading Central

1.99 / 2.635Soporte y Resistencia

Recent bearish events outweigh bullish events.

Bearish events outweigh bullish events.

Sentimiento

By Acuity

325 / 351 Clasificación en Sanidad

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

Acerca de AbCellera Biologics Inc

AbCellera Biologics Inc. builds an engine for antibody drug discovery and development. Its engine discovers antibodies from natural immune responses, which are pre-enriched for antibodies. The company's preclinical products are ABCL635 for metabolic and endocrine conditions; and ABCL575 for atopic dermatitis. It has a research collaboration and license agreement with Eli Lilly and Company; a research collaboration with Confo Therapeutics for the discovery of therapeutic antibody candidates targeting two undisclosed GPCR targets; and strategic collaboration with Biogen Inc. to discover therapeutic antibodies for neurological conditions, as well as collaboration with Viking Global Investors and ArrowMark Partners. The company was incorporated in 2012 and is headquartered in Vancouver, Canada.